Title : Finite-Element and Electromagnetic Cardio-Vascular Simulation for Drug Testing, Monitoring, and Safety Projection Using Bansal B–Bio Framework
Abstract:
Cardio-vascular drug testing and safety monitoring require more than isolated drug concentration, ECG interpretation, biomarker review, or conventional hemodynamic assessment. Drug response emerges through a coupled physiological environment involving cardiac anatomy, vascular geometry, blood flow, electrophysiology, electromagnetic behavior, plasma binding, hepatic metabolism, renal clearance, electrolyte balance, and toxicity-related trajectory deviation. This work presents a finite-element and electromagnetic cardio-vascular simulation approach using the Bansal B–Bio Framework for drug testing, monitoring, and safety projection.
The proposed model represents the heart, myocardium, valves, blood, arteries, arterioles, capillaries, venules, and veins as coupled finite-element domains. The framework is organized through the Bansal Unified Variational–Tensor Framework, where geometric elements, physiological fields, polynomial/basis structures, and clinical projection operators are arranged into a unified multiphysics simulation architecture. Within this structure, vascular flow, pressure, wall shear, stenosis, microvascular resistance, venous return, congestion, myocardial deformation, and electrophysiological behavior are treated as observable projections of the evolving cardio-vascular state.
A dedicated Bansal Electromagnetic component is incorporated to represent conductivity, permittivity, permeability, ionic-field behavior, magnetohydrodynamic contribution, electrohydrodynamic interaction, and electromagnetic influence on cardio-vascular and blood-mediated transport. In parallel, the B-Pharma and B-Phyto-Pharma Framework is used to represent drug behavior not merely as circulating concentration, but as a coupled pharmacological state involving free drug, protein-bound drug, lipid-bound drug, cell-associated drug, target interaction, ion-channel effect, metabolism, clearance, toxicity, antidote response, drug–drug interaction, and safety-alert projection.
B-Artificial Intelligence is positioned as an interpretability, pattern-support, and projection-assistance layer within the broader B–Bio system, supporting clinical review, signal organization, and safety monitoring.
This framework is designed to support interpretable clinician review by integrating anatomical geometry, vascular transport, electromagnetic response, pharmacological behavior, and drug-safety monitoring within a unified B–Bio modeling pathway. It is positioned as a review-supporting and software-oriented platform, distinct from clinical judgment, regulatory validation, or physician interpretation. The BVidAL Clinical Software Suite (Beta Version 0.16.600606) provides a foundation for SaMD-style simulation, cardiovascular digital-twin development, drug-testing workflows, monitoring systems, and safety projection across cardiac and vascular disease contexts.
